Volpara Health Technologies Limited provides breast imaging analytics and analysis products for the early detection of breast cancer in the medical device and practice management software industry worldwide.
No risks detected for VHT from our risk checks.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$1.24|
|52 Week High||AU$1.05|
|52 Week Low||AU$1.72|
|1 Month Change||-0.80%|
|3 Month Change||8.77%|
|1 Year Change||-17.06%|
|3 Year Change||-5.70%|
|5 Year Change||72.22%|
|Change since IPO||148.00%|
Recent News & Updates
Calculating The Intrinsic Value Of Volpara Health Technologies Limited (ASX:VHT)
In this article we are going to estimate the intrinsic value of Volpara Health Technologies Limited ( ASX:VHT ) by...
|VHT||AU Healthcare Services||AU Market|
Return vs Industry: VHT underperformed the Australian Healthcare Services industry which returned 46.7% over the past year.
Return vs Market: VHT underperformed the Australian Market which returned 20.2% over the past year.
Stable Share Price: VHT is less volatile than 75% of Australian stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: VHT's weekly volatility (5%) has been stable over the past year.
About the Company
Volpara Health Technologies Limited provides breast imaging analytics and analysis products for the early detection of breast cancer in the medical device and practice management software industry worldwide. The company offers Volpara Analytics software, a cloud-based breast imaging analytics platform that delivers performance monitoring solutions; Volpara Live, which provides radiographers instant patient-based image quality feedback; Volpara Lung, a patient management software; and Volpara Patient Hub, a customizable mammography reporting and patient communications software. It also offers Volpara Risk, an integration with Patient Hub that uses Tyrer-Cuzick v8 Risk Evaluation Tool to calculate patients’ risk of developing breast cancer; Volpara Scorecard, which displays patient breast density and risk insights essential for improved clinical decision-making and early detection; and Volpara Science, an AI-based software that powers Volpara software products.
Volpara Health Technologies Fundamentals Summary
|VHT fundamental statistics|
Is VHT overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|VHT income statement (TTM)|
|Cost of Revenue||NZ$1.69m|
Last Reported Earnings
Mar 31, 2021
Next Earnings Date
|Earnings per share (EPS)||-0.07|
|Net Profit Margin||-88.56%|
How did VHT perform over the long term?See historical performance and comparison
Is Volpara Health Technologies undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: VHT (A$1.24) is trading above our estimate of fair value (A$0.03)
Significantly Below Fair Value: VHT is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: VHT is unprofitable, so we can't compare its PE Ratio to the Global Healthcare Services industry average.
PE vs Market: VHT is unprofitable, so we can't compare its PE Ratio to the Australian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate VHT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: VHT is overvalued based on its PB Ratio (4.5x) compared to the AU Healthcare Services industry average (3.8x).
How is Volpara Health Technologies forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VHT is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.9%).
Earnings vs Market: VHT is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: VHT's is expected to become profitable in the next 3 years.
Revenue vs Market: VHT's revenue (30.8% per year) is forecast to grow faster than the Australian market (5.5% per year).
High Growth Revenue: VHT's revenue (30.8% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: VHT's Return on Equity is forecast to be low in 3 years time (7.6%).
How has Volpara Health Technologies performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: VHT is currently unprofitable.
Growing Profit Margin: VHT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: VHT is unprofitable, but has reduced losses over the past 5 years at a rate of 8.4% per year.
Accelerating Growth: Unable to compare VHT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VHT is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (39.5%).
Return on Equity
High ROE: VHT has a negative Return on Equity (-24.02%), as it is currently unprofitable.
How is Volpara Health Technologies's financial position?
Financial Position Analysis
Short Term Liabilities: VHT's short term assets (NZ$42.9M) exceed its short term liabilities (NZ$17.8M).
Long Term Liabilities: VHT's short term assets (NZ$42.9M) exceed its long term liabilities (NZ$4.0M).
Debt to Equity History and Analysis
Debt Level: VHT's debt to equity ratio (3.4%) is considered satisfactory.
Reducing Debt: VHT had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: VHT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if VHT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Volpara Health Technologies's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate VHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate VHT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if VHT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if VHT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of VHT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Dr. Ralph Highnam, BSc (Hons) 1st Class, MSc, PhD, serves as the Group Chief Executive Officer and Managing Director at Volpara Health Technologies Limited . He is the Founder of Volpara Health Technologie...
CEO Compensation Analysis
Compensation vs Market: Ralph's total compensation ($USD384.63K) is below average for companies of similar size in the Australian market ($USD556.28K).
Compensation vs Earnings: Ralph's compensation has increased whilst the company is unprofitable.
Experienced Management: VHT's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: VHT's board of directors are considered experienced (6.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Volpara Health Technologies Limited's employee growth, exchange listings and data sources
- Name: Volpara Health Technologies Limited
- Ticker: VHT
- Exchange: ASX
- Founded: 2009
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: AU$310.421m
- Shares outstanding: 251.35m
- Website: https://volparasolutions.com
Number of Employees
- Volpara Health Technologies Limited
- Simpl House
- Level 14
- New Zealand
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/18 07:05|
|End of Day Share Price||2021/10/18 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.